This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys

One small fund’s high-conviction move offers a window into how specialists are navigating 2025’s biotech rally.New York City-based Findell Capital Management disclosed a new $9.5 million position in Mineralys Therapeutics (MLYS +2.75%) as of its November 14 SEC filing.What HappenedAccording to a filing with the Securities and Exchange Commission dated November 14, Findell Capital Management initiated a new position in Mineralys Therapeutics (MLYS +2.75%), acquiring 250,000 shares in the third quarter. The s ...